Session Abstract – PMWC 2019 Silicon Valley
The PMWC 2019 Immunotherapy Showcase will take place on January 22 and January 23 and will provide a 15-minute time slot for selected immunotherapy companies to present their latest technologies and advancements to an audience of leading investors, potential clients, and partners. We will hear from companies building new cell-based immunotherapies, work in the growing area of cancer vaccines, that help understand the relevance of the tumor microenvironment, accelerate the patient selection process, or otherwise work towards overcoming to challenges related to therapeutic discovery.
Confirmed Presenting Companies:
- Ardigen
- Aduro Biotech
- ACT Genomics
- AIVITA Biomedical
- Adaptive Biotechnologies
- Boehringer-Ingelheim Pharmaceuticals
- Caris Life Sciences
- Cofactor Genomics
- Fate Therapeutics
- Fred Hutchinson Cancer Research Center
- Gritstone Oncology
- IGM Biosciences
- ImaginAb, Inc.
- Immix Biopharma Inc.
- Immune Design
- Kite, a Gilead Company
The PMWC 2019 Immunotherapy Showcase will take place on January 22 and January 23 and will provide a 15-minute time slot for selected immunotherapy companies to present their latest technologies and advancements to an audience of leading investors, potential clients, and partners. We will hear from companies building new cell-based immunotherapies, work in the growing area of cancer vaccines, that help understand the relevance of the tumor microenvironment, accelerate the patient selection process, or otherwise work towards overcoming to challenges related to therapeutic discovery.
Confirmed Presenting Companies:
- Ardigen
- Aduro Biotech
- ACT Genomics
- AIVITA Biomedical
- Adaptive Biotechnologies
- Boehringer-Ingelheim Pharmaceuticals
- Caris Life Sciences
- Cofactor Genomics
- Fate Therapeutics
- Fred Hutchinson Cancer Research Center
- Gritstone Oncology
- IGM Biosciences
- ImaginAb, Inc.
- Immix Biopharma Inc.
- Immune Design
- Kite, a Gilead Company
- MBL International
- MedGenome
- Microsoft Healthcare
- Minerva Biotechnologies
- Mitra Biotech
- Myriad RBM, Inc.
- Nektar Therapeutics
- Notable Labs
- OX2 Therapeutics
- Personalis
- RubrYc Therapeutics
- Stanford University
- T-Cure Bioscience, Inc
. - UCLA David Geffen School of Medicine
- Xcell Biosciences
- Yinuoke Ltd
Session Chair Profile
M.D., Vice President of Early Phase Development and Immuno-oncology, Eli Lilly and Company
Biography
Kimberly Blackwell is the Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology. A graduate of Mayo Clinic Medical School, Dr. Blackwell was Professor of Medicine and Assistant Professor of Radiation Oncology at Duke University Medical Center. She has played a major role in developing therapies that represent revolutionary non-chemotherapy based approaches for treating breast cancer. Her clinical and research interests include various topics in breast cancer including endocrine therapy, novel HER2 therapies, breast cancer vaccines, and other experimental therapeutics. She has studied and served as the principal investigator on studies that led to regulatory approval of four cancer agents, including the first biosimilar treatment for cancer in the United States. Due to her leadership, she has received numerous awards, including the Duke University Distinguished Alumni in 2015 and TIME Magazine’s 100 Most Influential People in the World in 2013. Additionally, Dr. Blackwell is a recipient of the Young Investigator Award in breast cancer from the National Cancer Institute Specialized Program of Research Excellence and the Joseph Greenfield Award for Mentorship of Clinical Research.
